Advertisement

Topics

Biocept, UT Southwestern to study liquid biopsy platform in ALK-positive non-small cell lung cancer

12:04 EDT 18 Aug 2017 | Healio

Biocept Inc. and University of Texas Southwestern Medical Center entered a clinical study agreement to evaluate the clinical utility of Biocept’s Target Selector platform for patients with ALK-positive non-small cell lung cancer.The liquid biopsy platform is designed to capture and analyze tumor-associated molecular markers in both circulating tumor cells and circulating tumor DNA to identify cancer mutations and alterations that can inform physicians about a patient's disease and potential therapeutic options.

Original Article: Biocept, UT Southwestern to study liquid biopsy platform in ALK-positive non-small cell lung cancer

NEXT ARTICLE

More From BioPortfolio on "Biocept, UT Southwestern to study liquid biopsy platform in ALK-positive non-small cell lung cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...